Healthcare
HBM Holdings Limited(HBMHF)
Live Price
Offline$1.56
+0.00% today
1Y Change
+41.82%
Window
Jun 25, 2025 → Jun 23, 2026
- Market Cap
- $1.39B
- Revenue Growth
- -57.4%
- EPS Growth
- -88.4%
- Dividend Yield
- 0.0%
Coverage: 253 bars · Jun 25, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
HBM Holdings Limited (HBMHF) is a Healthcare stock with a market cap of $1.39B and listed on OTC. The stock last traded around $1.56 and up 41.8% across the available one-year price window (Jun 25, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of -57.4%, EPS growth of -88.4%, a dividend yield of 0.0%. What stands out right now is revenue -57.4%, EPS -88.4%, free cash flow +240.9% with operating margin 47.1% and ROIC 8.2%. Valuation already assumes a fairly strong business story at P/E 34.9 and price/sales 21.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HBMHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-57.4% vs +7.6% peer median
Operating Margin
Above sector median
+47.1% vs +19.4% peer median
P/E
Near sector median
34.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -57.4% and EPS is at -88.4%, with operating margin around 47.1%.
Benchmark Edge
HBMHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HBMHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HBMHF Max Drawdown
-38.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HBMHF and SPY.
Company Overview
HBM Holdings Limited
Other OTC
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
- Leadership
- Jingsong Wang
- IPO Date
- Mar 24, 2022
- Employees
- 183
- Street Address
- Tower A, 12th Floor
- Mailing
- Shanghai, 200032
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 5339 9123
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 34.9
- EV/EBITDA
- 34.7
- Price/Sales
- 21.3
- Price/Book
- 4.6
Growth
- Revenue
- -57.4%
- EPS
- -88.4%
- Free Cash Flow
- +240.9%
Profitability
- Gross Margin
- 91.2%
- Operating Margin
- 47.1%
- Net Margin
- 57.2%
- ROE
- 18.3%
- ROIC
- 8.2%
Balance Sheet
- Debt/Equity
- 0.23
- Current Ratio
- 6.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.